Fischer Medical Ventures Limited has informed the Exchange regarding Board meeting held on August 14, 2025.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures held its board meeting on August 14, 2025, and approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. On a standalone basis, revenue from operations came in at ₹454.23 lakhs, down from ₹521.97 lakhs in the previous quarter, and the company posted a loss of ₹60.94 lakhs with negative EPS of ₹0.09. On a consolidated basis (including subsidiaries like Time Medical and FMV entities), revenue from operations was ₹1,152.83 lakhs and total income was ₹3,091.11 lakhs, resulting in a profit of ₹500.82 lakhs and EPS of ₹0.36. The board also fixed September 29, 2025 as the date for the 32nd AGM via video conferencing, with share transfer books closed from September 23-29, 2025. M/s Nuren Lodaya & Associates was appointed as scrutinizer for the AGM and recommended as secretarial auditor for a five-year term. Independent Director Dr. Jacob Thomas resigned effective end of day August 14, 2025, citing personal reasons.
The standalone business remains loss-making, but strong consolidated profitability driven by subsidiaries paints a more positive picture for the group. Investors should watch the AGM for further clarity, and note that the independent board vacancy following Dr. Thomas's resignation could raise governance concerns until filled.